- Home
- BMEA vs IVA Comparison
BMEA vs IVA Comparison
Compare BMEA & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- IVA
- Stock Information
- Founded
- BMEA 2017
- IVA 2011
- Country
- BMEA United States
- IVA France
- Employees
- BMEA N/A
- IVA N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- BMEA Health Care
- IVA Health Care
- Exchange
- BMEA Nasdaq
- IVA Nasdaq
- Market Cap
- BMEA 145.0M
- IVA 127.0M
- IPO Year
- BMEA 2021
- IVA 2020
- Fundamental
- Price
- BMEA $3.46
- IVA $2.84
- Analyst Decision
- BMEA Buy
- IVA Strong Buy
- Analyst Count
- BMEA 13
- IVA 4
- Target Price
- BMEA $27.92
- IVA $13.25
- AVG Volume (30 Days)
- BMEA 414.8K
- IVA 10.9K
- Earning Date
- BMEA 03-31-2025
- IVA 03-26-2025
- Dividend Yield
- BMEA N/A
- IVA N/A
- EPS Growth
- BMEA N/A
- IVA N/A
- EPS
- BMEA N/A
- IVA N/A
- Revenue
- BMEA N/A
- IVA $20,652,523.00
- Revenue This Year
- BMEA N/A
- IVA N/A
- Revenue Next Year
- BMEA N/A
- IVA $197.46
- P/E Ratio
- BMEA N/A
- IVA N/A
- Revenue Growth
- BMEA N/A
- IVA N/A
- 52 Week Low
- BMEA $3.25
- IVA $1.53
- 52 Week High
- BMEA $19.36
- IVA $4.50
- Technical
- Relative Strength Index (RSI)
- BMEA 34.96
- IVA 69.74
- Support Level
- BMEA $3.25
- IVA $2.58
- Resistance Level
- BMEA $3.75
- IVA $2.80
- Average True Range (ATR)
- BMEA 0.24
- IVA 0.15
- MACD
- BMEA 0.00
- IVA 0.04
- Stochastic Oscillator
- BMEA 21.43
- IVA 81.31
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.